Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

PVLAPALVELLA THERAPEUTICS, INC.

Nasdaq · CIK 0001583648
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts430

Identity from submissions API

NamePALVELLA THERAPEUTICS, INC.
CIK0001583648
TickersPVLA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN300784346
LEI—
Fiscal year end1231
State of incorporationNV NV
Phone(484) 253-1461
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)1

Former names

  • PIERIS PHARMACEUTICALS, INC. (2014-12-23T00:00:00.000Z → 2024-12-12T00:00:00.000Z)
  • Marika Inc. (2013-08-20T00:00:00.000Z → 2014-12-18T00:00:00.000Z)
Business address
353 W. LANCASTER AVENUE
SUITE 200
WAYNE
PA
19087
PA
Mailing address
353 W. LANCASTER AVENUE
SUITE 200
WAYNE
PA
19087
PA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

820 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-19 8-K 8-K 7.01,8.01,9.01 0001193125-26-467823 001-37471 261572326 34 8989645 1 1
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-001584 005-88917 261561430 34 33821
2026-11-12 4 OWNERSHIP DOCUMENT 0001104659-26-126376 41617
2026-11-10 144 xsl144X01/primary_doc.xml 0001950047-26-010958 001-37471 261540839 33 5311
2026-11-05 10-Q 10-Q 0001193125-26-448638 001-37471 261524891 34 8415626 1 1
2026-11-05 8-K 8-K 2.02,7.01,9.01 0001193125-26-448594 001-37471 261524801 34 10415159 1 1
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000053417-26-000064 005-88917 261495567 34 6914
2026-10-28 8-K 8-K 8.01,9.01 0001193125-26-435113 001-37471 261492441 34 265697 1 1
2026-10-23 4 OWNERSHIP DOCUMENT 0001104659-26-118466 17815
2026-10-21 144 xsl144X01/primary_doc.xml 0001967940-26-000055 001-37471 261475947 33 6716
2026-10-14 4 OWNERSHIP DOCUMENT 0001104659-26-115916 39740
2026-10-13 144 xsl144X01/primary_doc.xml 0001967940-26-000053 001-37471 261457509 33 6701
2026-09-18 4 OWNERSHIP DOCUMENT 0001104659-26-108930 17822
2026-09-16 144 xsl144X01/primary_doc.xml 0001967940-26-000051 001-37471 261384144 33 6751
2026-09-15 4 OWNERSHIP DOCUMENT 0001104659-26-108022 24041
2026-09-11 144 xsl144X01/primary_doc.xml 0001967940-26-000050 001-37471 261374781 33 4790
2026-09-04 4 OWNERSHIP DOCUMENT 0001104659-26-105494 9253
2026-09-02 144 xsl144X01/primary_doc.xml 0001950047-26-008991 001-37471 261354857 33 5009
2026-08-20 4 OWNERSHIP DOCUMENT 0001104659-26-099222 21370
2026-08-19 144 xsl144X01/primary_doc.xml 0001967940-26-000044 001-37471 261296123 33 6715
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001999371-26-018011 005-88917 261282705 34 14483
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-002180 005-88917 261282060 34 23640
2026-08-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001137774-26-000180 005-88917 261257790 34 7959
2026-08-04 S-8 FORM S-8 0001104659-26-090394 333-297957 261239037 33 223749 1 1
2026-08-04 10-Q 10-Q 0001193125-26-331574 001-37471 261235537 34 7687421 1 1
2026-08-04 8-K 8-K 2.02,7.01,9.01 0001193125-26-331556 001-37471 261235475 34 12366138 1 1
2026-08-03 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000053417-26-000050 005-88917 261231012 34 6779
2026-07-29 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002924 005-88917 261216983 34 11291
2026-07-17 4 OWNERSHIP DOCUMENT 0001104659-26-084620 19859
2026-07-15 144 xsl144X01/primary_doc.xml 0001967940-26-000039 001-37471 261177595 33 6751
2026-07-14 8-K 8-K 8.01,9.01 0001193125-26-303307 001-37471 261174776 34 29318917 1 1
2026-07-01 4 OWNERSHIP DOCUMENT 0001104659-26-079865 5873
2026-07-01 3 OWNERSHIP DOCUMENT 0001104659-26-079863 8874
2026-06-30 8-K FORM 8-K 5.02 0001104659-26-079087 001-37471 261137995 34 193331 1 1
2026-06-22 4 OWNERSHIP DOCUMENT 0001104659-26-076460 17299
2026-06-17 144 xsl144X01/primary_doc.xml 0001967940-26-000032 001-37471 261099438 33 6751
2026-06-16 4 OWNERSHIP DOCUMENT 0001104659-26-074574 7444
2026-06-16 8-K FORM 8-K 5.02,5.07,9.01 0001104659-26-074338 001-37471 261092959 34 223391 1 1
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073443 6043
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073442 6064
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073437 6021
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073432 6046
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073426 6049
2026-06-12 4 OWNERSHIP DOCUMENT 0001104659-26-073420 6062
2026-05-22 4 OWNERSHIP DOCUMENT 0001104659-26-065692 17299
2026-05-20 144 xsl144X01/primary_doc.xml 0001967940-26-000016 001-37471 261005276 33 6126
2026-05-20 8-K 8-K 8.01,9.01 0001193125-26-232717 001-37471 261004568 34 259209 1 1
2026-05-15 8-K 8-K 8.01,9.01 0001193125-26-225317 001-37471 26982251 34 244854 1 1
2026-05-13 8-K 8-K 8.01 0001193125-26-220607 001-37471 26970934 34 148326 1 1
2026-05-07 8-K 8-K 2.02,7.01,9.01 0001193125-26-210605 001-37471 26951183 34 14504783 1 1
2026-05-07 10-Q 10-Q 0001193125-26-210463 001-37471 26951035 34 6324772 1 1
2026-04-30 ARS ARS 0001104659-26-052938 001-37471 26925508 34 26401492
2026-04-30 DEFA14A DEFA14A 0001104659-26-052923 001-37471 26925418 34 481501
2026-04-30 DEF 14A DEF 14A 0001104659-26-052875 001-37471 26925070 34 3855640 1 1
2026-04-17 4 OWNERSHIP DOCUMENT 0001104659-26-044895 21372
2026-04-15 4 OWNERSHIP DOCUMENT 0001104659-26-043793 5872
2026-04-15 3 OWNERSHIP DOCUMENT 0001104659-26-043788 10261
2026-04-15 144 xsl144X01/primary_doc.xml 0001967940-26-000009 001-37471 26864069 33 6786
2026-04-13 8-K 8-K 5.02 0001193125-26-151979 001-37471 26856438 34 155450 1 1
2026-04-07 8-K 8-K 8.01,9.01 0001193125-26-144540 001-37471 26842912 34 22766215 1 1
2026-04-01 4 OWNERSHIP DOCUMENT 0001104659-26-038496 5887
2026-03-31 10-K 10-K 0001193125-26-133372 001-37471 26817225 34 18500053 1 1
2026-03-31 8-K 8-K 2.02,7.01,9.01 0001193125-26-133332 001-37471 26817102 34 11304524 1 1
2026-03-20 4 OWNERSHIP DOCUMENT 0001104659-26-032695 17752
2026-03-18 144 xsl144X01/primary_doc.xml 0001967940-26-000008 001-37471 26768665 33 6493
2026-03-02 4 OWNERSHIP DOCUMENT 0001104659-26-021922 5988
2026-03-02 4 OWNERSHIP DOCUMENT 0001104659-26-021921 5824
2026-02-26 8-K FORM 8-K 1.01,9.01 0001104659-26-020667 001-37471 26690697 34 584662 1 1
2026-02-26 424B5 424B5 0001104659-26-020659 333-292544 26690682 33 749795
2026-02-24 424B5 424B5 0001104659-26-019152 333-292544 26672052 33 790600
2026-02-24 8-K FORM 8-K 2.02 0001104659-26-019143 001-37471 26671945 34 189605 1 1
2026-02-24 8-K 8-K 7.01,9.01 0001193125-26-065308 001-37471 26667583 34 12204270 1 1
2026-02-24 8-K 8-K 8.01,9.01 0001193125-26-065159 001-37471 26667383 34 1330419 1 1
2026-02-20 4 OWNERSHIP DOCUMENT 0001104659-26-018136 15643
2026-02-19 144/A xsl144X01/primary_doc.xml 0001967940-26-000005 001-37471 26655853 33 6793
2026-02-18 144 xsl144X01/primary_doc.xml 0001967940-26-000004 001-37471 26648036 33 6490
2026-02-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001999371-26-003517 005-88917 26642412 34 14525
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-26-000471 005-88917 26641812 34 24177
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001231919-26-000151 005-88917 26634860 34 44342
2026-02-09 4 OWNERSHIP DOCUMENT 0001104659-26-012068 5881
2026-02-09 4 OWNERSHIP DOCUMENT 0001104659-26-012067 5904
2026-02-09 4 OWNERSHIP DOCUMENT 0001104659-26-012066 5867
2026-02-09 4 OWNERSHIP DOCUMENT 0001104659-26-012064 5872
2026-02-09 4 OWNERSHIP DOCUMENT 0001104659-26-012060 5872
2026-01-29 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-000347 333-292544 26580311 33 2063
2026-01-29 8-K 8-K 8.01,9.01 0001193125-26-029341 001-37471 26577972 34 26471144 1 1
2026-01-27 CORRESP filename1.htm 0001104659-26-006806 7686
2026-01-23 4 OWNERSHIP DOCUMENT 0001104659-26-006237 14605
2026-01-21 144 xsl144X01/primary_doc.xml 0001967940-26-000002 001-37471 26548328 33 6133
2026-01-12 8-K 8-K 8.01,9.01 0001193125-26-009724 001-37471 26524619 34 26528147 1 1
2026-01-05 UPLOAD filename1.pdf 0000000000-26-000081 333-292544 40418
2026-01-02 S-3 S-3 0001104659-26-000065 333-292544 26500216 33 1036464 1 1
2025-12-19 4 OWNERSHIP DOCUMENT 0001104659-25-123109 13591
2025-12-17 144 xsl144X01/primary_doc.xml 0001967940-25-000095 001-37471 251579754 33 5469
2025-12-15 8-K FORM 8-K 7.01,8.01,9.01 0001104659-25-120789 001-37471 251569906 34 2697336 1 1
2025-11-21 4 OWNERSHIP DOCUMENT 0001104659-25-115017 15144
2025-11-19 144 xsl144X01/primary_doc.xml 0001967940-25-000085 001-37471 251499922 33 4804
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000921895-25-003114 005-88917 251486671 34 25622
2025-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-25-006758 005-88917 251479935 34 17220
2025-11-12 10-Q 10-Q 0001193125-25-276119 001-37471 251469343 34 7784800 1 1
2025-11-10 8-K 8-K 2.02,7.01,9.01 0001193125-25-274378 001-37471 251466714 34 9394739 1 1
2025-11-05 8-K FORM 8-K 7.01,8.01,9.01 0001104659-25-106591 001-37471 251451599 34 4853553 1 1
2025-09-24 8-K FORM 8-K 7.01,9.01 0001104659-25-092681 001-37471 251335117 34 257279 1 1
2025-09-03 8-K 8-K 7.01,9.01 0001104659-25-086685 001-37471 251287755 34 12445235 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-021969 005-88917 251221195 34 12050
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-021793 005-88917 251217130 34 44022
2025-08-14 10-Q 10-Q 0000950170-25-108438 001-37471 251214422 34 7503102 1 1
2025-08-14 8-K 8-K 2.02,7.01,9.01 0000950170-25-108422 001-37471 251214346 34 6041862 1 1
2025-06-11 4 PRIMARY DOCUMENT 0001583648-25-000042 5352
2025-06-11 4 PRIMARY DOCUMENT 0001583648-25-000041 5231
2025-06-11 4 PRIMARY DOCUMENT 0001583648-25-000040 5357
2025-06-11 4 PRIMARY DOCUMENT 0001583648-25-000039 5312
2025-06-11 4 PRIMARY DOCUMENT 0001583648-25-000038 5338
2025-06-11 8-K FORM 8-K 5.07 0001104659-25-058532 001-37471 251039961 34 197536 1 1
2025-06-03 4 PRIMARY DOCUMENT 0001583648-25-000030 7746
2025-06-03 3 PRIMARY DOCUMENT 0001583648-25-000029 6030
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-012986 005-88917 25949383 34 57750
2025-05-15 10-Q 10-Q 0000950170-25-071998 001-37471 25948752 34 6640117 1 1
2025-05-15 8-K 8-K 2.02,7.01,9.01 0000950170-25-071988 001-37471 25948720 34 8151575 1 1
2025-04-30 ARS ARS 0001104659-25-042518 001-37471 25895331 34 2253996
2025-04-30 DEFA14A DEFA14A 0001104659-25-042506 001-37471 25895076 34 425565
2025-04-30 DEF 14A FORM DEF 14A 0001104659-25-042493 001-37471 25894961 34 3662108 1 1
2025-04-10 4 PRIMARY DOCUMENT 0001583648-25-000025 6330
2025-03-31 10-K 10-K 0000950170-25-047212 001-37471 25788958 34 16757349 1 1
2025-03-31 8-K 8-K 2.02,7.01,9.01 0000950170-25-047206 001-37471 25788921 34 12924153 1 1
2025-03-04 8-K FORM 8-K 7.01,9.01 0001437749-25-006013 001-37471 25701603 34 7606534 1 1
2025-02-18 S-8 FORM S-8 0001437749-25-004229 333-285029 25635674 33 169228
2025-02-10 4/A PRIMARY DOCUMENT 0001583648-25-000023 5779
2025-02-10 4/A PRIMARY DOCUMENT 0001583648-25-000021 7826
2025-02-10 4/A PRIMARY DOCUMENT 0001583648-25-000019 7807
2025-02-10 4/A PRIMARY DOCUMENT 0001583648-25-000017 7824
2025-02-07 4 PRIMARY DOCUMENT 0001583648-25-000015 001-37471 25602328 34 8180
2025-02-07 4 PRIMARY DOCUMENT 0001583648-25-000014 001-37471 25602298 34 8175
2025-02-07 4 PRIMARY DOCUMENT 0001583648-25-000013 001-37471 25602256 34 6149
2025-02-07 4 PRIMARY DOCUMENT 0001583648-25-000012 001-37471 25602250 34 8174
2025-01-17 424B3 FORM 424B3 0001437749-25-001381 333-284093 25538735 33 5645984
2025-01-16 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000134 333-284093 25536871 33 2058
2025-01-15 CORRESP filename1.htm 0001437749-25-001170 12809
2025-01-14 S-1/A FORM S-1/A 0001437749-25-001017 333-284093 25527680 33 15232206 1 1
2025-01-13 8-K FORM 8-K 7.01,9.01 0001437749-25-000924 001-37471 25524732 34 9797515 1 1
2025-01-08 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-001108 005-88917 25518214 34 56380
2025-01-06 3/A AMENDED INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-000400 485798
2025-01-03 UPLOAD filename1.pdf 0000000000-25-000059 333-284093 40463
2024-12-31 S-1 FORM S-1 0001437749-24-038553 333-284093 241591074 33 25650195 1 1
2024-12-20 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001437749-24-038167 005-88917 241569090 34 39190
2024-12-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-24-029979 005-88917 241568725 34 14424
2024-12-20 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000919574-24-007251 005-88917 241568701 34 16939
2024-12-19 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020879 6010
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020823 5481
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020822 5521
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020821 5509
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020820 5528
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020819 5516
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020818 5596
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020817 5524
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020816 5511
2024-12-17 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020815 502498
2024-12-17 4 OWNERSHIP DOCUMENT 0000921895-24-002972 51500
2024-12-17 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0000921895-24-002971 005-88917 241556953 34 284392
2024-12-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001943462-24-000010 005-88917 241555964 34 76469
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020699 515939
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020698 505395
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020697 489403
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020696 1098456
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020695 1109962
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020694 1093811
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020693 1088939
2024-12-16 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-020692 447484
2024-12-16 4 PRIMARY DOCUMENT 0001943462-24-000008 3986
2024-12-16 8-K FORM 8-K 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.05,5.06,8.01,9.01 0001437749-24-037515 001-37471 241549973 34 9122597 1 1
2024-12-12 4 FORM 4 (GERAGHTY SERIES F) 0001437749-24-037353 4875
2024-12-12 425 FORM 425 0001437749-24-037352 001-37471 241545000 34 1467781
2024-12-12 8-K FORM 8-K 3.03,5.02,5.03,5.07,8.01,9.01 0001437749-24-037350 001-37471 241544971 34 1640425 1 1
2024-12-09 4 FORM 4 (ANNUAL GRANT) 0001437749-24-036916 5071
2024-12-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001943462-24-000007 005-88917 241531836 34 76974
2024-12-03 425 FORM 425 0001437749-24-036507 001-37471 241521248 34 68382
2024-12-03 8-K FORM 8-K 5.07,8.01,9.01 0001437749-24-036506 001-37471 241521246 34 217131 1 1
2024-11-18 3 PRIMARY DOCUMENT 0001943462-24-000005 4883
2024-11-14 SC 13G/A PIERIS PHARMACEUTICALS, INC. 0000902664-24-006519 005-88917 241457639 34 66871
2024-11-13 10-Q FORM 10-Q 0001437749-24-034891 001-37471 241453901 34 5138303 1 1
2024-11-12 SEC STAFF LETTER filename1.pdf 9999999997-24-004381 64320
2024-11-08 EFFECT xslEFFECTX01/primary_doc.xml S-4,,2024-11-08 17:00:00 9999999995-24-003418 333-281459 241442670 33 1857
2024-11-08 424B3 FORM 424B3 0001437749-24-034238 333-281459 241441780 33 11820517
2024-11-07 425 FORM 425 0001437749-24-033781 001-37471 241433435 34 27748
2024-11-07 CORRESP filename1.htm 0001437749-24-033779 13616
2024-11-07 S-4/A FORM S-4/A 0001437749-24-033778 333-281459 241433401 33 12046131
2024-11-06 DEF 14A FORM DEF 14A 0001437749-24-033669 001-37471 241432015 34 1526880
2024-11-06 ARS FORM ARS 0001437749-24-033668 001-37471 241431995 34 1341524
2024-11-05 CORRESP filename1.htm 0001437749-24-033378 20013
2024-11-05 S-4/A FORM S-4/A 0001437749-24-033377 333-281459 241428413 33 12048171
2024-11-04 UPLOAD filename1.pdf 0000000000-24-012240 333-281459 44228
2024-10-29 CORRESP filename1.htm 0001437749-24-032371 43400
2024-10-29 S-4/A FORM S-4/A 0001437749-24-032370 333-281459 241402797 33 13351300
2024-10-28 4 FORM 4 (SERIES F) 0001437749-24-032319 5219
2024-10-25 SEC STAFF LETTER filename1.pdf 9999999997-24-004216 65350
2024-10-25 UPLOAD filename1.pdf 0000000000-24-011959 333-281459 55893
2024-10-17 425 FORM 425 0001437749-24-031428 001-37471 241375941 34 30715
2024-10-15 CORRESP filename1.htm 0001437749-24-031190 43422
2024-10-15 S-4/A FORM S-4/A 0001437749-24-031189 333-281459 241369441 33 12530736
2024-10-15 425 FORM 425 0001437749-24-031186 001-37471 241369351 34 30284
2024-10-09 UPLOAD filename1.pdf 0000000000-24-011415 333-281459 58476
2024-10-03 425 FORM 425 0001437749-24-030560 001-37471 241349930 34 53999
2024-10-03 8-K FORM 8-K 8.01,9.01 0001437749-24-030559 001-37471 241349926 34 198983 1 1
2024-09-23 CORRESP filename1.htm 0001437749-24-029799 117381
2024-09-23 S-4/A FORM S-4/A 0001437749-24-029789 333-281459 241314568 33 11957764
2024-09-06 UPLOAD filename1.pdf 0000000000-24-010139 333-281459 103458
2024-08-14 10-Q FORM 10-Q 0001437749-24-026778 001-37471 241207294 34 5490349 1 1
2024-08-12 4 PRIMARY DOCUMENT 0001940272-24-000006 11481
2024-08-09 S-4 FORM S-4 0001437749-24-025929 333-281459 241194153 33 12494789
2024-08-08 425 FORM 425 0001437749-24-025566 001-37471 241188664 34 1602063
2024-08-08 8-K FORM 8-K 1.01,3.02,3.03,5.03,9.01 0001437749-24-025565 001-37471 241188653 34 1757126 1 1
2024-08-07 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001943462-24-000004 005-88917 241182943 34 15729
2024-08-01 SC 13G SC 13G 0001104659-24-084642 005-88917 241164413 34 85249
2024-07-31 3 PRIMARY DOCUMENT 0001758866-24-000005 7934
2024-07-24 425 FORM 425 0001437749-24-023302 001-37471 241136059 34 6735767
2024-07-24 8-K FORM 8-K 1.01,3.02,5.02,8.01,9.01 0001437749-24-023301 001-37471 241136057 34 7265388 1 1
2024-07-03 8-K FORM 8-K 1.02,8.01,9.01 0001437749-24-022188 001-37471 241100541 34 171332 1 1
2024-05-17 SC 13G THE SCHEDULE 13G 0000921895-24-001271 005-88917 24961207 34 294934
2024-05-17 SC 13G THE SCHEDULE 13G 0000921895-24-001270 005-88917 24961202 34 294934
2024-05-15 10-Q FORM 10-Q 0001437749-24-017037 001-37471 24950163 34 5333556 1 1
2024-05-09 8-K FORM 8-K 8.01 0001437749-24-015466 001-37471 24928663 34 160394 1 1
2024-04-29 10-K/A FORM 10-K/A 0001437749-24-013736 001-37471 24892177 34 805032 1 1
2024-04-18 8-K FORM 8-K 3.03,5.03,7.01,9.01 0001437749-24-012442 001-37471 24854561 34 681804 1 1
2024-03-29 10-K FORM 10-K 0001437749-24-010123 001-37471 24804919 34 8087118 1 1
2024-03-27 8-K FORM 8-K 2.02,8.01,9.01 0001437749-24-009491 001-37471 24785835 34 202263 1 1
2024-02-14 SC 13G/A pirs_13gv3.htm 0001591986-24-000003 005-88917 24639395 34 83651
2024-02-14 SC 13G/A pirs_13gv3.htm 0001977548-24-000005 005-88917 24635368 34 79927
2024-02-14 SC 13G/A PIERIS PHARMACEUTICALS, INC. 0000902664-24-001607 005-88917 24633026 34 64945
2024-02-02 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0001213900-24-009385 005-88917 24589098 34 105363
2023-12-21 8-K FORM 8-K 1.02,9.01 0001437749-23-035107 001-37471 231505706 34 165810 1 1
2023-11-14 10-Q FORM 10-Q 0001437749-23-031957 001-37471 231405684 34 5532222 1 1
2023-08-31 8-K/A FORM 8-K/A 2.05,9.01 0001437749-23-024952 001-37471 231229220 34 169024 1 1
2023-08-17 SC 13D/A AMENDMENT NO. 1 TO THE SCHEDULE 13D 0000921895-23-001997 005-88917 231182641 34 290441
2023-08-10 S-8 S-8 0001193125-23-209166 333-273893 231160532 33 101545
2023-08-10 10-Q FORM 10-Q 0001437749-23-023085 001-37471 231159924 34 5562745 1 1
2023-07-18 8-K FORM 8-K 1.02,2.02,2.05,8.01,9.01 0001437749-23-020094 001-37471 231093137 34 200908 1 1
2023-07-13 8-K FORM 8-K 5.02,9.01 0001437749-23-019831 001-37471 231085736 34 162806 1 1
2023-06-26 8-K FORM 8-K 5.02,5.07,9.01 0001437749-23-018518 001-37471 231043309 34 423176 1 1
2023-06-23 4 FORM 4 0001437749-23-018284 5142
2023-06-23 4 FORM 4 0001437749-23-018283 5152
2023-06-23 4 FORM 4 0001437749-23-018282 5098
2023-06-23 4 FORM 4 0001437749-23-018281 5020
2023-06-23 4 FORM 4 0001437749-23-018280 5114
2023-06-23 4 FORM 4 0001437749-23-018279 5152
2023-06-23 4 FORM 4 0001437749-23-018278 5155
2023-06-21 8-K FORM 8-K 2.02,8.01,9.01 0001437749-23-017908 001-37471 231027385 34 184029 1 1
2023-06-12 SC 13G pirsv3_13g.htm 0001977548-23-000002 005-88917 231006545 34 93310
2023-06-08 8-K FORM 8-K 7.01,9.01 0001437749-23-016922 001-37471 231000582 34 3259719 1 1
2023-05-30 4 PRIMARY DOCUMENT 0001562180-23-004575 4609
2023-05-22 3 OWNERSHIP DOCUMENT 0000921895-23-001312 48785
2023-05-22 SC 13D SCHEDULE 13D 0000921895-23-001309 005-88917 23945218 34 335177
2023-05-19 8-K 8-K 3.01 0001193125-23-149296 001-37471 23940030 34 146616 1 1
2023-05-11 10-Q FORM 10-Q 0001437749-23-013687 001-37471 23908086 34 5133388 1 1
2023-05-10 8-K FORM 8-K 2.02,7.01,9.01 0001437749-23-013408 001-37471 23904340 34 3804142 1 1
2023-04-28 ARS formars2.pdf 0001437749-23-011632 001-37471 23866505 34 3948230
2023-04-28 DEFA14A FORM DEFA14A 0001437749-23-011631 001-37471 23866445 34 448187
2023-04-28 DEF 14A FORM DEF 14A 0001437749-23-011629 001-37471 23866386 34 1339040
2023-03-31 10-K FORM 10-K 0001437749-23-008834 001-37471 23787391 34 10175167 1 1
2023-03-29 8-K FORM 8-K 2.02,7.01,9.01 0001437749-23-008303 001-37471 23771764 34 7363344 1 1
2023-02-28 4 230228 FORM 4 (BURES) 0001437749-23-004963 5163
2023-02-28 4 230228 FORM 4 (KAUFMANN) 0001437749-23-004958 5171
2023-02-28 4 230228 FORM 4 (MOUSA) 0001437749-23-004953 5142
2023-02-28 4 230228 FORM 4 (OLWILL) 0001437749-23-004948 5166
2023-02-28 4 230228 FORM 4 (YODER) 0001437749-23-004940 5222
2023-02-14 SC 13G/A PIERIS PHARMACEUTICALS, INC. 0000902664-23-001799 005-88917 23628908 34 66198
2023-02-14 SC 13G/A pirs_13gv4.htm 0001591986-23-000004 005-88917 23624778 34 80870
2023-02-14 SC 13G/A AMENDMENT NO. 9 TO THE SCHEDULE 13G 0000921895-23-000484 005-88917 23621319 34 287479
2023-02-10 SC 13G/A SC 13G/A 0001193125-23-032632 005-88917 23612223 34 43460
2023-02-10 SC 13G/A SC 13G/A 0001104659-23-018079 005-88917 23609131 34 56093
2023-01-27 SC 13G SC 13G 0001193125-23-017729 005-88917 23564074 34 101941
2023-01-26 SC 13G/A SC 13G/A 0001193125-23-016327 005-88917 23558488 34 92743
2023-01-10 8-K FORM 8-K 7.01,9.01 0001437749-23-000801 001-37471 23521494 34 178132 1 1
2023-01-03 CT ORDER filename1.pdf 20221221,20230103 9999999997-22-005020 001-37471 221478558 34 164380
2023-01-03 CT ORDER filename1.pdf 20221221,20230103 9999999997-22-005017 001-37471 221478191 34 161651
2023-01-03 CT ORDER filename1.pdf 20221221,20230103 9999999997-22-005015 001-37471 221478186 34 161236
2022-12-16 CT ORDER filename1.pdf 20221216,20221216 9999999997-22-005007 001-37471 221466973 34 160806
2022-11-04 424B5 424B5 0001193125-22-278012 333-258497 221363041 33 441046
2022-11-04 8-K FORM 8-K 1.01,9.01 0001437749-22-026051 001-37471 221362704 34 226149 1 1
2022-11-04 10-Q FORM 10-Q 0001437749-22-026023 001-37471 221362247 34 5868895 1 1
2022-11-02 8-K FORM 8-K 2.02,7.01,9.01 0001437749-22-025458 001-37471 221352317 34 8092635 1 1
2022-11-01 8-K FORM 8-K 7.01,9.01 0001437749-22-025278 001-37471 221348714 34 178272 1 1
2022-10-24 SC 13G PIERIS PHARMACEUTICALS, INC. 0000902664-22-004631 005-88917 221326466 34 68341
2022-09-13 8-K 8-K 7.01,9.01 0001583648-22-000067 001-37471 221239775 34 4416227 1 1
2022-08-04 S-8 S-8 0001193125-22-212640 333-266539 221137619 33 86728
2022-08-04 10-Q 10-Q 0001583648-22-000065 001-37471 221136938 34 7072549 1 1
2022-08-04 8-K 8-K 5.02,9.01 0001583648-22-000061 001-37471 221134905 34 173902 1 1
2022-08-04 8-K 8-K 2.02,7.01,9.01 0001583648-22-000059 001-37471 221134655 34 4169033 1 1
2022-07-06 10-K/A 10-K/A 0001583648-22-000057 001-37471 221069791 34 539338 1 1
2022-06-27 8-K 8-K 5.02,5.07,9.01 0001583648-22-000055 001-37471 221041330 34 361703 1 1
2022-06-24 4 FORM 4 0001583648-22-000054 296246
2022-06-24 4 FORM 4 0001583648-22-000053 5420
2022-06-24 4 FORM 4 0001583648-22-000052 296676
2022-06-24 4 FORM 4 0001583648-22-000051 296150
2022-06-24 4 FORM 4 0001583648-22-000050 294711
2022-06-24 4 FORM 4 0001583648-22-000049 295003
2022-06-24 4 FORM 4 0001583648-22-000048 5423
2022-06-08 8-K 8-K 7.01,9.01 0001583648-22-000034 001-37471 221002600 34 4314824 1 1
2022-05-25 8-K 8-K 7.01,9.01 0001583648-22-000032 001-37471 22958900 34 3939958 1 1
2022-05-16 4 FORM 4 0001583648-22-000030 4793
2022-05-12 8-K/A 8-K/A 7.01,9.01 0001583648-22-000027 001-37471 22914946 34 9752599 1 1
2022-05-11 10-Q 10-Q 0001583648-22-000025 001-37471 22914318 34 14451112 1 1
2022-05-11 8-K 8-K 2.02,7.01,9.01 0001583648-22-000023 001-37471 22912101 34 9966354 1 1
2022-04-29 DEFA14A DEFA14A 0001583648-22-000020 001-37471 22875375 34 1179969
2022-04-29 DEF 14A DEF 14A 0001583648-22-000019 001-37471 22875206 34 1689539
2022-03-02 10-K 10-K 0001583648-22-000016 001-37471 22700659 34 13253457 1 1
2022-03-01 8-K 8-K 2.02,7.01,9.01 0001583648-22-000012 001-37471 22693931 34 9951003 1 1
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001876 8901
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001874 8905
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001873 8915
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001872 8907
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001871 8927
2022-02-24 4 PRIMARY DOCUMENT 0001562180-22-001870 8929
2022-02-14 SC 13G/A pirs_13gv1.htm 0001591986-22-000007 005-88917 22630394 34 80518
2022-02-14 SC 13G/A AMENDMENT NO. 8 TO THE SCHEDULE 13G 0000921895-22-000539 005-88917 22629177 34 305270
2022-02-14 SC 13G/A PIERIS PHARMACEUTICALS, INC. 0001104659-22-021293 005-88917 22624749 34 140127
2022-02-14 SC 13G/A AMENDMENT NO.1 TO SCHEDULE 13G 0001213900-22-007167 005-88917 22624495 34 144418
2022-01-27 SC 13G SC 13G 0001193125-22-019851 005-88917 22563584 34 103519
2022-01-24 8-K 8-K 2.02,7.01,9.01 0001583648-22-000010 001-37471 22547561 34 9269416 1 1
2022-01-14 8-K 8-K 7.01,9.01 0001583648-22-000007 001-37471 22530476 34 204425 1 1
2022-01-14 8-K/A 8-K/A 7.01,9.01 0001583648-22-000006 001-37471 22530474 34 175214 1 1
2022-01-03 8-K 8-K 8.01,9.01 0001583648-22-000002 001-37471 22500378 34 204859 1 1
2021-11-18 8-K 8-K 7.01,9.01 0001583648-21-000051 001-37471 211422625 34 8795032
2021-11-02 10-Q 10-Q 0001583648-21-000047 001-37471 211371330 34 17870005 1 1
2021-11-02 8-K 8-K 2.02,9.01 0001583648-21-000044 001-37471 211369251 34 1905990 1 1
2021-10-21 3 PRIMARY DOCUMENT 0001562180-21-006607 13512
2021-10-06 8-K 8-K 5.02,8.01,9.01 0001193125-21-292635 001-37471 211308837 34 172523 1 1
2021-09-01 4 PRIMARY DOCUMENT 0001562180-21-005712 13740
2021-08-30 8-K 8-K 7.01,9.01 0001583648-21-000041 001-37471 211221446 34 3817127 1 1
2021-08-24 8-K 8-K 7.01,8.01,9.01 0001583648-21-000039 001-37471 211198912 34 1351066 1 1
2021-08-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-08-13 16:00:00 9999999995-21-003203 333-258497 211174178 33 1800
2021-08-11 CORRESP filename1.htm 0001193125-21-243157 7180
2021-08-11 UPLOAD filename1.pdf 0000000000-21-009807 40242
2021-08-05 S-8 S-8 0001193125-21-237847 333-258502 211149164 33 256795
2021-08-05 S-3 S-3 0001193125-21-237835 333-258497 211149101 33 1276421
2021-08-05 10-Q 10-Q 0001583648-21-000034 001-37471 211148058 34 51494828 1 1
2021-08-04 8-K 8-K 2.02,7.01,9.01 0001583648-21-000030 001-37471 211142334 34 10233834 1 1
2021-08-03 4 PRIMARY DOCUMENT 0001562180-21-005129 8934
2021-08-03 3 PRIMARY DOCUMENT 0001562180-21-005128 6519
2021-08-03 3 PRIMARY DOCUMENT 0001562180-21-005125 15097
2021-07-12 SC 13G/A us7207951036_071021.txt 0000834237-21-008731 005-88917 211084421 34 12241
2021-07-06 SC 13G PIERIS PHARMACEUTICALS, INC. 0001104659-21-089388 005-88917 211074067 34 159793
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004564 5607
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004563 9091
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004562 5571
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004561 5477
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004560 5599
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004559 5605
2021-06-29 4 PRIMARY DOCUMENT 0001562180-21-004558 5600
2021-06-29 8-K 8-K 5.02,5.07,9.01 0001193125-21-203278 001-37471 211058254 34 301477 1 1
2021-06-25 8-K 8-K 7.01,9.01 0001628280-21-012877 001-37471 211044710 34 9744631 1 1
2021-06-01 424B3 424B3 0001193125-21-178493 333-256218 21985201 33 138746
2021-05-28 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-05-28 16:00:00 9999999995-21-002161 333-256218 21982691 33 1799
2021-05-26 CORRESP filename1.htm 0001193125-21-173331 7173
2021-05-25 8-K 8-K 7.01,9.01 0001583648-21-000028 001-37471 21957391 34 6815852 1 1
2021-05-25 8-K 8-K 1.01,9.01 0001583648-21-000026 001-37471 21957386 34 1037701 1 1
2021-05-21 8-K 8-K 1.01,3.02,3.03,5.03,9.01 0001193125-21-169379 001-37471 21949808 34 404880 1 1
2021-05-19 UPLOAD filename1.pdf 0000000000-21-006366 40241
2021-05-17 S-3 S-3 0001193125-21-163947 333-256218 21932560 33 223963
2021-05-17 10-Q 10-Q 0001583648-21-000023 001-37471 21931200 34 77476954 1 1
2021-05-17 8-K 8-K 2.02,9.01 0001583648-21-000018 001-37471 21927503 34 1911493 1 1
2021-04-29 DEFA14A DEFA14A 0001583648-21-000016 001-37471 21870371 34 1208146
2021-04-29 DEF 14A DEF 14A 0001583648-21-000015 001-37471 21870332 34 1348933
2021-04-26 8-K 8-K 1.01,9.01 0001583648-21-000009 001-37471 21851863 34 1016285 1 1
2021-04-12 8-K 8-K 7.01,9.01 0001583648-21-000007 001-37471 21819656 34 10674799 1 1
2021-04-08 SC 13G SC 13G 0001104659-21-047684 005-88917 21813179 34 107417
2021-04-02 SC 13G SC 13G 0001193125-21-105170 005-88917 21802210 34 43799
2021-03-31 10-K 10-K 0001583648-21-000005 001-37471 21794642 34 18604766 1 1
2021-03-30 8-K 8-K 2.02,7.01,9.01 0001628280-21-006064 001-37471 21783646 34 9351787 1 1
2021-03-30 8-K 8-K 1.01,3.02 0001628280-21-006061 001-37471 21783611 34 188987 1 1
2021-03-25 8-K 8-K 1.01,3.02,8.01,9.01 0001583648-21-000002 001-37471 21770250 34 1379589 1 1
2021-03-08 4 PRIMARY DOCUMENT 0001562180-21-002058 9082
2021-03-08 4 PRIMARY DOCUMENT 0001562180-21-002057 9109
2021-03-08 4 PRIMARY DOCUMENT 0001562180-21-002056 5613
2021-02-16 SC 13G/A pirs_13g.htm 0001591986-21-000005 005-88917 21638527 34 80407
2021-02-16 SC 13G SCHEDULE 13G 0001213900-21-009249 005-88917 21632455 34 164809
2021-02-12 SC 13G/A AMENDMENT NO. 7 TO THE SCHEDULE 13G 0000921895-21-000382 005-88917 21627802 34 312145
2021-01-29 SC 13G/A us7207951036_012921.txt 0000834237-21-004873 005-88917 21572816 34 13227
2020-12-15 8-K 8-K 7.01,9.01 0001583648-20-000065 001-37471 201388272 34 6206993 1 1
2020-11-04 10-Q 10-Q 0001583648-20-000061 001-37471 201287561 34 18450088 1 1
2020-11-04 8-K 8-K 2.02,9.01 0001583648-20-000057 001-37471 201285150 34 1803126 1 1
2020-09-21 8-K 8-K 7.01,9.01 0001583648-20-000055 001-37471 201185587 34 4410824 1 1
2020-09-21 8-K 8-K 7.01,9.01 0001583648-20-000053 001-37471 201185198 34 3251364 1 1
2020-09-09 8-K 8-K 7.01,9.01 0001583648-20-000050 001-37471 201165680 34 5604496 1 1
2020-08-10 S-8 S-8 0001193125-20-215001 333-243735 201090065 33 85829
2020-08-10 10-Q 10-Q 0001583648-20-000046 001-37471 201089770 34 7956175 1 1
2020-08-10 8-K 8-K 2.02,9.01 0001583648-20-000044 001-37471 201087139 34 329662 1 1
2020-08-10 8-K 8-K 1.01,9.01 0001583648-20-000042 001-37471 201087135 34 225731 1 1
2020-08-07 CT ORDER filename1.pdf 20200807,20200807 9999999997-20-004330 001-37471 201083947 34 124053
2020-07-22 4 PRIMARY DOCUMENT 0001591986-20-000011 5811
2020-07-20 8-K 8-K 8.01,9.01 0001583648-20-000039 001-37471 201036584 34 226814 1 1
2020-06-29 8-K 8-K 5.02,5.07,9.01 0001583648-20-000037 001-37471 20997952 34 5543527 1 1
2020-06-25 4/A PRIMARY DOCUMENT 0001562180-20-004696 5531
2020-06-25 4/A PRIMARY DOCUMENT 0001562180-20-004695 9145
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004693 9068
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004692 5587
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004691 5548
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004689 5454
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004688 5577
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004687 5582
2020-06-25 4 PRIMARY DOCUMENT 0001562180-20-004686 5578

Latest XBRL company facts

One latest value per concept from companyfacts (430 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 14.62M 2026-11-02 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
dei EntityPublicFloat Entity Public Float USD 196.70M 2025-06-30 2025 FY 10-K 2026-03-31 0001193125-26-133372
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 21.47M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001104659-26-052875
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.98M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001104659-26-052875
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 125.81 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001104659-26-052875
ffd NetFeeAmt NetFeeAmt USD 14,393.82 2026-08-04 S-8 2026-08-04 0001104659-26-090394
ffd TtlFeeAmt TtlFeeAmt USD 14,393.82 2026-08-04 S-8 2026-08-04 0001104659-26-090394
ffd TtlOfferingAmt TtlOfferingAmt USD 104.23M 2026-08-04 S-8 2026-08-04 0001104659-26-090394
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-04 S-8 2026-08-04 0001104659-26-090394
us-gaap AccountsPayableAndOtherAccruedLiabilitiesCurrent Accounts Payable and Other Accrued Liabilities, Current USD 10.79M 2022-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 5.16M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AccountsPayableTradeCurrent Accounts Payable, Trade, Current USD 4.52M 2016-09-30 2016 Q3 10-Q 2016-11-10 0001193125-16-765868
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 524,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AccruedBonusesCurrent Accrued Bonuses, Current USD 252,953 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap AccruedEnvironmentalLossContingenciesNoncurrent Accrued Environmental Loss Contingencies, Noncurrent USD 5,581 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap AccruedIncomeTaxes Accrued Income Taxes USD 1.06M 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 23,852 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 19.68M 2021-09-30 2021 Q3 10-Q 2021-11-02 0001583648-21-000047
us-gaap AccruedLiabilitiesCurrentAndNoncurrent Accrued Liabilities USD 1.76M 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 392,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 704,597 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 9.65M 2022-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 56,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 395.58M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 316.25M 2022-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap AdditionalPaidInCapitalPreferredStock Additional Paid in Capital, Preferred Stock USD 22,750 2014-09-30 2015 Q1 10-Q 2014-11-13 0001583648-14-000012
us-gaap AdjustmentOfWarrantsGrantedForServices Adjustment of Warrants Granted for Services USD 664,064 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 5.42M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 5,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 13.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 500,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap AssetBackedSecuritiesAtCarryingValue Asset-Backed Securities, at Carrying Value USD 7.95M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap Assets Assets USD 239.40M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AssetsCurrent Assets, Current USD 238.97M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AssetsHeldForSaleNotPartOfDisposalGroupCurrent Assets Held-for-sale, Not Part of Disposal Group, Current USD 0 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 367,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 407,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 43.42M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 41.89M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 57,000 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax USD 127,000 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 53.38M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 43.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap AvailableForSaleSecuritiesGrossRealizedGainLossNet Available-for-sale Securities, Gross Realized Gain (Loss) USD 0 2017-01-01 2017-06-30 2018 Q2 10-Q 2018-08-09 0001583648-18-000049
us-gaap BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Business Acquisition, Transaction Costs USD 2.50M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets USD 14.75M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents USD 13.78M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets USD 14.75M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets USD 595,000 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables USD 377,000 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities USD 3.14M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable USD 142,000 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities USD 3.14M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net USD 11.61M 2024-12-13 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001437749-24-026778
us-gaap CapitalizedContractCostAmortization Capitalized Contract Cost, Amortization USD 100,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap Cash Cash USD 89.92M 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 193.30M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 11.89M 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 36.99M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 236.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 54.26M 2022-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 193.30M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 135.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 34.90M 2021-09-30 2021 Q3 10-Q 2021-11-02 0001583648-21-000047
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 2 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 123,238 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap CommercialPaperAtCarryingValue Commercial Paper, at Carrying Value USD 10.91M 2018-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 14.61M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 14.61M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap CommonStockValue Common Stock, Value, Issued USD 15,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -62.31M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ContractWithCustomerAssetGross Contract with Customer, Asset, before Allowance for Credit Loss USD 1.10M 2017-05-02 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap ContractWithCustomerAssetNet Contract with Customer, Asset, after Allowance for Credit Loss USD 300,000 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized USD 38.70M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001437749-23-031957
us-gaap ConvertibleNotesPayable Convertible Notes Payable USD 18.43M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 13.34 2024-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap CostsAndExpenses Costs and Expenses USD 7.61M 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap CostsAndExpensesRelatedParty Costs and Expenses, Related Party USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption Cumulative Effect of New Accounting Principle in Period of Adoption (Deprecated 2020-01-31) USD -1.64M 2019-01-01 2020 Q1 10-Q 2020-05-11 0001583648-20-000026
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 4.38M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature USD 2.24M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DebtInstrumentFairValue Debt Instrument, Fair Value Disclosure USD 0 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss USD 300,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Position 7 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredIncomeTaxesAndTaxCredits Deferred Income Taxes and Tax Credits USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 1.00M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap DeferredRentAssetNetCurrent Deferred Rent Asset, Net, Current USD 12.10M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001583648-19-000075
us-gaap DeferredRentReceivablesNet Deferred Rent Receivables, Net USD 0 2019-01-01 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 35.61M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap DeferredRevenueNoncurrent Deferred Revenue, Noncurrent USD 53.30M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 0 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 106.68M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 106.14M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsNetNoncurrent Deferred Tax Assets, Net of Valuation Allowance, Noncurrent USD 24,464 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 91.96M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsForeign Deferred Tax Assets, Operating Loss Carryforwards, Foreign USD 8.90M 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 10,149 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 12,065 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 199,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsOther Deferred Tax Assets, Tax Credit Carryforwards, Other USD 589,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 644,000 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits USD 2.62M 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 1.79M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsTaxDeferredExpenseOther Deferred Tax Assets, Tax Deferred Expense, Other USD 102,935 2013-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Provision for Loan Losses USD 12,653 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves USD 35,888 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap DeferredTaxAssetsUnrealizedCurrencyLosses Deferred Tax Assets, Unrealized Currency Losses USD 377,000 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 106.14M 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxAssetsValuationAllowanceNoncurrent Deferred Tax Assets, Valuation Allowance, Noncurrent USD -5,435 2014-06-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap DeferredTaxLiabilitiesCurrent Deferred Tax Liabilities, Net, Current USD 24,464 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap DeferredTaxLiabilitiesDeferredExpense Deferred Tax Liabilities, Deferred Expense USD 0 2022-12-31 2022 FY 10-K 2023-03-31 0001437749-23-008834
us-gaap DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals Deferred Tax Liabilities, Deferred Expense, Reserves and Accruals USD 8,811 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 400,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap DeferredTaxLiabilitiesPrepaidExpenses Deferred Tax Liabilities, Prepaid Expenses USD 9,438 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 30,646 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Deferred Tax Liabilities, Unrealized Gains on Trading Securities USD 0 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 45,000 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-15 0001583648-18-000017
us-gaap Depreciation Depreciation USD 1.80M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DepreciationAmortizationAndAccretionNet Depreciation, Amortization and Accretion, Net USD -30,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 1.90M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap DerivativeLiabilitiesCurrent Derivative Liability, Current USD 2.60M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 1.37M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 15,986 2014-06-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap DueToOfficersOrStockholdersNoncurrent Due to Officers or Stockholders, Noncurrent USD 3.10M 2013-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap DueToRelatedPartiesNoncurrent Due to Related Parties, Noncurrent USD 474 2014-09-30 2015 Q1 10-Q 2014-11-13 0001583648-14-000012
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -4.45 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.07 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001583648-21-000023
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -4.45 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.206 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.008 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.021 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure -0.01 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent pure 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.042 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure -0.014 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations USD -1.58M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD -111,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 3,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 3.04M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 4.30M 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 61.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap FairValueOptionChangesInFairValueGainLoss1 Fair Value, Option, Changes in Fair Value, Gain (Loss) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap ForeignCurrencyTransactionGainLossUnrealized Foreign Currency Transaction Gain (Loss), Unrealized USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap GainLossOnContractTermination Gain (Loss) on Contract Termination USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 200,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 26.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap GovernmentAssistanceAmount GovernmentAssistanceAmount USD 500,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap GovernmentAssistanceOperatingIncome GovernmentAssistanceOperatingIncome USD 600,000 2025-10-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap GrantsReceivable Grants Receivable USD 600,000 2025-10-31 2025 Q3 10-Q 2025-11-12 0001193125-25-276119
us-gaap GrantsReceivableCurrent Grants Receivable, Current USD 0 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -41.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -62.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 64,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -37.07M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 1,206 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current USD 3,534 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap IncomeTaxExaminationPenaltiesAndInterestExpense Income Tax Examination, Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 8.58M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 420,337 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 4,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -8.76M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 330,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 408,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncomeTaxReconciliationPriorYearIncomeTaxes Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount USD 7.31M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 564,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 650 2013-05-24 2014-06-30 2014 FY 10-K 2014-09-12 0001583648-14-000010
us-gaap IncreaseDecreaseInAccountsPayableTrade Increase (Decrease) in Accounts Payable, Trade USD 496,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 1,250 2013-07-01 2013-09-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 2.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-14 0001437749-23-031957
us-gaap IncreaseDecreaseInDeferredRevenue Increase (Decrease) in Deferred Revenue USD -39.97M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap IncreaseDecreaseInDerivativeLiabilities Increase (Decrease) in Derivative Liabilities USD 1.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInIncomeTaxes Increase (Decrease) in Income Taxes USD 10,109 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-10 0001193125-16-765868
us-gaap IncreaseDecreaseInOperatingCapital Increase (Decrease) in Operating Capital USD -89,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -148,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 768,905 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD 628,723 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap IncreaseDecreaseInPrepaidRent Increase (Decrease) in Prepaid Rent USD 0 2019-01-01 2019-09-30 2020 Q3 10-Q 2020-11-04 0001583648-20-000061
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD -70,026 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap InterestExpense Interest Expense USD 4,223 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap InterestExpenseDebt Interest Expense, Debt USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap InterestIncomeExpenseNet Interest Income (Expense), Net USD 5.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 610,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 206,269 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 0 2013-07-01 2013-09-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 11.50M 2019-01-01 2019-03-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap LeaseCost Lease, Cost USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap LegalFees Legal Fees USD 29,087 2013-05-24 2014-09-30 2015 Q1 10-Q 2014-11-13 0001583648-14-000012
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 736,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 262,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 205,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 269,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 522,000 2023-09-30 2023 Q3 10-Q 2023-11-14 0001437749-23-031957
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 103,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap LessorOperatingLeaseLeaseNotYetCommencedAssumptionAndJudgmentValueOfUnderlyingAssetAmount Lessor, Operating Lease, Lease Not yet Commenced, Assumption and Judgment, Value of Underlying Asset, Amount USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap Liabilities Liabilities USD 41.48M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 239.40M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap LiabilitiesCurrent Liabilities, Current USD 14.93M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap LiabilityForUncertainTaxPositionsCurrent Liability for Uncertainty in Income Taxes, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap LicenseAndServicesRevenue License and Services Revenue (Deprecated 2018-01-31) USD 26.68M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap LitigationReserveNoncurrent Estimated Litigation Liability, Noncurrent USD 327,937 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap LoansPayableCurrent Loans Payable, Current USD 3,474 2014-09-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap LoansPayableToBankCurrent Loans Payable to Bank, Current USD 0 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap LongTermInvestments Long-term Investments USD 0 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap LongTermLoansFromBank Loans Payable to Bank, Noncurrent USD 1.45M 2013-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap LossContingencyAccrualAtCarryingValue Loss Contingency Accrual USD 327,937 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap LossContingencyDamagesAwardedValue Loss Contingency, Damages Awarded, Value EUR 3.50M 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value EUR 2.50M 2014-12-23 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap MoneyMarketFundsAtCarryingValue Money Market Funds, at Carrying Value USD 47.38M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 216.46M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 48.50M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -42.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -3.66M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -38.14M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD 7.99M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -62.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -29.00M 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-276119
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -17.43M 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD -2.65M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap NumberOfPropertiesSubjectToGroundLeases Number of Properties Subject to Ground Leases Sublease 6 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-331574
us-gaap OperatingExpenses Operating Expenses USD 58.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -58.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OperatingLeaseCost Operating Lease, Cost USD 61,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 633,000 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 225,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 260,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OperatingLeasePayments Operating Lease, Payments USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 435,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD -91,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-02 0001583648-22-000016
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 36.02M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 613,000 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 2.37M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 2.35M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 2.46M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 2.46M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 25.77M 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 300,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.116 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 15,986 2014-06-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.03M 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OtherAccruedLiabilitiesNoncurrent Other Accrued Liabilities, Noncurrent USD 23,852 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap OtherAssetsCurrent Other Assets, Current USD 1.29M 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD 152,000 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent USD 100,000 2019-01-01 2019-03-31 2020 Q1 10-Q 2020-05-11 0001583648-20-000026
us-gaap OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax USD 13,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -1,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD -19,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD -985,885 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap OtherComprehensiveIncomeLossTax Other Comprehensive Income (Loss), Tax USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -1,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OtherCostAndExpenseOperating Other Cost and Expense, Operating USD 817 2013-05-26 2014-09-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap OtherDepreciationAndAmortization Other Depreciation and Amortization USD 1.43M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap OtherGeneralExpense Other General Expense USD 48 2013-05-24 2013-12-31 2014 Q2 10-Q 2014-05-14 0001583648-14-000005
us-gaap OtherIncome Other Income USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 1.34M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 0 2023-06-30 2023 Q2 10-Q 2023-08-10 0001437749-23-023085
us-gaap OtherNoncashIncomeExpense Other Noncash Income (Expense) USD -864,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -46,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap OtherReceivablesNetCurrent Other Receivables, Net, Current USD 506,000 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap OtherSalesRevenueNet Other Revenue, Net (Deprecated 2018-01-31) USD 91,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap PaidInKindInterest Paid-in-Kind Interest USD 2.59M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap PartnersCapitalAccountUnitsSoldInPrivatePlacement Partners' Capital Account, Units, Sold in Private Placement shares 8.19M 2016-06-01 2016-06-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap PaymentForContingentConsiderationLiabilityFinancingActivities Payment for Contingent Consideration Liability, Financing Activities USD 1.98M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 14.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PaymentsOfMergerRelatedCostsFinancingActivities Payments of Merger Related Costs, Financing Activities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 154,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 74.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-276119
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 2.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 589,928 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376834
us-gaap ProceedsFromContributionsFromAffiliates Proceeds from Contributions from Affiliates USD 474 2013-05-24 2014-09-30 2015 Q1 10-Q 2014-11-13 0001583648-14-000012
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 25.80M 2015-07-01 2015-07-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 230.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 7.34M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 32.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans Proceeds from Repayment of Loans by Employee Stock Ownership Plans USD 145,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-04 0001583648-20-000061
us-gaap ProceedsFromRepaymentsOfDebt Proceeds from (Repayments of) Debt USD 1.36M 2014-01-01 2014-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 64.49M 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap ProceedsFromSaleOfProductiveAssets Proceeds from Sale of Productive Assets USD 2.32M 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 10,888 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 2.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-31 0001437749-23-008834
us-gaap ProfessionalFees Professional Fees USD 29,087 2013-05-26 2014-09-30 2015 Q1 10-Q 2014-12-12 0001477932-14-007008
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -62.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 26.64M 2022-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap RealizedInvestmentGainsLosses Realized Investment Gains (Losses) USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock Receivable from Shareholders or Affiliates for Issuance of Capital Stock USD 1.81M 2021-09-30 2021 Q3 10-Q 2021-11-02 0001583648-21-000047
us-gaap RepaymentOfNotesReceivableFromRelatedParties Repayment of Notes Receivable from Related Parties USD 0 2013-05-24 2014-03-31 2014 Q3 10-Q 2014-06-02 0001583648-14-000007
us-gaap RepaymentsOfDebt Repayments of Debt USD 1.16M 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned Research and Development Arrangement, Contract to Perform for Others, Compensation Earned USD 1.76M 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 32.63M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 0 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap RestrictedStockExpense Restricted Stock or Unit Expense USD 446,400 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -197.73M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer USD 47,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 43.65M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap RevenueFromContractWithCustomerIncludingAssessedTax Revenue from Contract with Customer, Including Assessed Tax USD 6,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap RevenueFromGrants Revenue from Grants (Deprecated 2018-01-31) USD 369,200 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap RevenueNotFromContractWithCustomer Revenue Not from Contract with Customer USD -192,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-11 0001583648-22-000025
us-gaap RevenueRecognitionMilestoneMethodRevenueRecognized Revenue Recognition, Milestone Method, Revenue Recognized USD 571,000 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-18 0001583648-19-000011
us-gaap Revenues Revenues USD 53,000 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 8 2018-02-28 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap SalesRevenueGoodsNet Sales Revenue, Goods, Net (Deprecated 2018-01-31) USD 0 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-13 0001193125-17-339158
us-gaap SecurityDeposit Security Deposit USD 800,000 2018-12-31 2019 Q3 10-Q 2019-11-12 0001583648-19-000075
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 13.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 138.88 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.751 2015-01-01 2015-03-31 2016 Q1 10-Q 2016-05-12 0001193125-16-588539
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.209 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.744 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.017 2015-01-01 2015-03-31 2016 Q1 10-Q 2016-05-12 0001193125-16-588539
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.002 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.001 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number shares 25,918 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 9.97M 2018-07-24 2018 Q3 10-Q 2018-11-07 0001583648-18-000074
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 9.28M 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 174.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 1.21M 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 2.06 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 1,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 0 2015-04-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 0 2015-04-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 112,500 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.73M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 67.03 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 391.80M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 2.71M 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 2.05 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 741,000 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 2.71M 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 2.05 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 543,926 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 375,319 2015-01-01 2015-06-30 2015 Q2 10-Q 2015-08-13 0001193125-15-290039
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 0.85 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 2 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 2 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 2.47 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap SharesPaidForTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation shares 938 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShortTermInvestments Short-term Investments USD 43.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 53,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 197.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD -904 2014-09-30 2015 Q1 10-Q 2014-11-13 0001583648-14-000012
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 2.273 2014-12-05 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap StockIssuedDuringPeriodSharesConversionOfUnits Stock Issued During Period, Shares, Conversion of Units shares 1 2016-06-01 2016-06-30 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Stock Issued During Period, Shares, Employee Stock Purchase Plans shares 154,656 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 279,075 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 11.61M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 70.60M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap StockIssuedDuringPeriodValueConversionOfUnits Stock Issued During Period, Value, Conversion of Units USD 0 2021-01-01 2021-06-30 2022 Q2 10-Q 2022-08-04 0001583648-22-000065
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 52,000 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-13 0001437749-24-034891
us-gaap StockIssuedDuringPeriodValueIssuedForServices Stock Issued During Period, Value, Issued for Services USD 225,000 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 215.75M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 446,400 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-30 0001193125-17-102052
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 452,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap StockRedeemedOrCalledDuringPeriodShares Stock Redeemed or Called During Period, Shares shares 11.36M 2014-12-17 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased shares 542,360 2015-12-31 2015 FY 10-K 2016-03-23 0001193125-16-514870
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 20.66M 2022-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap TradingSecurities Debt Securities, Trading, and Equity Securities, FV-NI USD 28.64M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-31 0000950170-25-047212
us-gaap UnrealizedGainLossOnDerivatives Unrealized Gain (Loss) on Derivatives USD -1.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments USD -40,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation USD 302,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-31 0001437749-23-008834
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities USD 5.36M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0001437749-24-010123
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 125,000 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation USD 103,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001583648-21-000005
us-gaap USGovernmentSecuritiesAtCarryingValue US Government Securities, at Carrying Value USD 5.30M 2019-12-31 2019 FY 10-K 2020-03-13 0001583648-20-000015
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 12.88M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap VariableLeaseCost Variable Lease, Cost USD 12,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-31 0001193125-26-133372
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 0 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-14 0001437749-24-026778
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 14.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 56.30M 2021-01-01 2021-03-31 2021 Q1 10-Q 2021-05-17 0001583648-21-000023
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 14.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448638
us-gaap WorkersCompensationLiabilityCurrent Workers' Compensation Liability, Current USD 319,031 2013-12-31 2014 FY 10-K 2015-03-30 0001193125-15-109883

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →